Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU

Amgen’s first biosimilar – a competitor to AbbVie’s Humira – and three would-be competitors to Amgen’s own Neulasta are among the 17 biosimilar products that are under evaluation at the European Medicines Agency.

Biosimilar versions of several blockbuster drugs, including AbbVie’s Humira (adalimumab), Roche’s Herceptin (trastuzumab) and Avastin (bevacizumab), and Amgen’s Neulasta (pegfilgrastim) are under review at the European Medicines Agency.

The EMA publishes a monthly table of products that are under evaluation by the agency’s scientific committee, the CHMP, although...